PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2
Received date: 2023-08-23
Revised date: 2023-11-08
Online published: 2023-12-05
Supported by
National Natural Science Foundation of China(82002573);National Natural Science Foundation of China(82172707);National Key Research and Development Program of China(2017YFA0504301)
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer accounting for 90% of cases. It is a highly invasive and deadly cancer with a gradual onset. Polypyrimidine tract-binding protein 1 (PTBP1) is an important RNA-binding protein involved in RNA metabolism and has been linked to oncogenic splicing events. While the oncogenic role of PTBP1 in HCC cells has been established, the exact mechanism of action remains unclear. This study aimed to investigate the functional connection between PTBP1 and dysregulated splicing events in HCC. Through immunoprecipitation-mass spectrometry analyses, we discovered that the proteins bound to PTBP1 were significantly enriched in the complex responsible for the alternative splicing of FGFR2 (fibroblast growth factor receptor 2). Further RNA immunoprecipitation and quantitative PCR assays confirmed that PTBP1 down-regulated the FGFR2-IIIb isoform levels and up-regulated the FGFR2-IIIc isoform levels in HCC cells, leading to a switch from FGFR2-IIIb to FGFR2-IIIc isoforms. Subsequent functional evaluations using CCK-8, transwell, and plate clone formation assays in HCC cell lines HepG2 and Huh7 demonstrated that FGFR2-IIIb exhibited tumor-suppressive effects, while FGFR2-IIIc displayed tumor-promoting effects. In conclusion, this study provides insights into the PTBP1-mediated alternative splicing mechanism in HCC progression, offering a new theoretical basis for the prevention and treatment of this malignancy. Mechanistically, the isoform switch from FGFR2-IIIb to FGFR2-IIIc promoted epithelial-mesenchymal transformation (EMT) of HCC cells and activated the FGFR cascades ERK and AKT pathways.
Key words： hepatocellular carcinoma; PTBP1; alternative splicing; FGFR2; epithelial-mesenchymal
Yuying Chen, Qian Zhang, Menghui Gui, Lan Feng, Pengbo Cao, Gangqiao Zhou . PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2[J]. Hereditas(Beijing), 2024 , 46(1) : 46 -62 . DOI: 10.16288/j.yczz.23-224
| [1] | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249. |
| [2] | Qiu HB, Cao SM, Xu RH. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond), 2021, 41(10): 1037-1048. |
| [3] | Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J, 2014, 35(29): 1925-1931. |
| [4] | Guan Z, Cheng W, Huang D, Wei A. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma. Curr Res Transl Med, 2018, 66(1): 27-32. |
| [5] | Tang R, Wu JC, Zheng LM, Li ZR, Zhou KL, Zhang ZS, Xu DF, Chen C. Long noncoding RNA RUSC1-AS-N indicates poor prognosis and increases cell viability in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 2018, 22(2): 388-396. |
| [6] | Cheung HC, Hai T, Zhu W, Baggerly KA, Tsavachidis S, Krahe R, Cote GJ. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain, 2009, 132(Pt 8): 2277-2288. |
| [7] | Takahashi H, Nishimura J, Kagawa Y, Kano Y, Takahashi Y, Wu X, Hiraki M, Hamabe A, Konno M, Haraguchi N, Takemasa I, Mizushima T, Ishii M, Mimori K, Ishii H, Doki Y, Mori M, Yamamoto H. Significance of polypyrimidine tract-binding protein 1 expression in colorectal cancer. Mol Cancer Ther, 2015, 14(7): 1705-1716. |
| [8] | Ferrarese R, Harsh GR 4th, Yadav AK, Bug E, Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP, Dai FP, Kim H, Hadler M, Scholtens DM, Yu ILY, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, von Elverfeldt D, Backofen R, Weyerbrock A, Duarte CW, He XL, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich JN, Carro MS, Bredel M,. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest, 2014, 124(7): 2861-2876. |
| [9] | Kang H, Heo S, Shin JJ, Ji E, Tak H, Ahn S, Lee KJ, Lee EK, Kim W. A miR-194/PTBP1/CCND3 axis regulates tumor growth in human hepatocellular carcinoma. J Pathol, 2019, 249(3): 395-408. |
| [10] | Wu DG, He XT, Wang WJ, Hu XT, Wang KF, Wang MH. Long noncoding RNA SNHG12 induces proliferation, migration, epithelial-mesenchymal transition, and stemness of esophageal squamous cell carcinoma cells via post-transcriptional regulation of BMI1 and CTNNB1. Mol Oncol, 2020, 14(9): 2332-2351. |
| [11] | Li T, Jin XZ, Dong JR, Deng HB. Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer. J Gene Med, 2020, 22(10): e3241. |
| [12] | Wei L, Wang XW, Lv LY, Liu JB, Xing HX, Song YM, Xie MY, Lei TS, Zhang NS, Yang M. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer, 2019, 18(1): 147. |
| [13] | Gao G, Dai C, Yu X, Yin XB, Zhou F. Long noncoding RNA LINC00324 exerts protumorigenic effects on liver cancer stem cells by upregulating fas ligand via PU box binding protein. FASEB J, 2020, 34(4): 5800-5817. |
| [14] | Khadirnaikar S, Chatterjee A, Kumar P, Shukla S. A greedy algorithm-based stem cell lncRNA signature identifies a novel subgroup of lung adenocarcinoma patients with poor pognosis. Front Oncol, 2020, 10: 1203. |
| [15] | Lu GM, Rong YX, Liang ZJ, Hunag DL, Ma YF, Luo ZZ, Wu FX, Liu XH, Liu Y, Mo S, Qi ZQ, Li HM. Multiomics global landscape of stemness-related gene clusters in adipose-derived mesenchymal stem cells. Stem Cell Res Ther, 2020, 11(1): 310. |
| [16] | Sun LK, Wang L, Chen TX, Shi Y, Yao BW, Liu ZK, Wang YF, Li Q, Liu RK, Niu YS, Tu KS, Liu QG. LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells. Cell Death Dis, 2020, 11(2): 95. |
| [17] | Shen LH, Lei SJ, Zhang B, Li SG, Huang LY, Czachor A, Breitzig M, Gao YM, Huang MY, Mo XM, Zheng Q, Sun HX, Wang F. Skipping of exon 10 in Axl pre-mRNA regulated by PTBP1 mediates invasion and metastasis process of liver cancer cells. Theranostics, 2020, 10(13): 5719-5735. |
| [18] | He ZT, Ni QH, Li XC, Zhao MY, Mo QG, Duo YS. PTBP1 promotes hepatocellular carcinoma progression by regulating the skipping of exon 9 in NUMB pre-mRNA. Heliyon, 2023, 9(6): e17387. |
| [19] | Guo JC, Yang YJ, Zheng JF, Zhang JQ, Guo M, Yang X, Jiang XL, Xiang L, Li Y, Ping H, Zhuo L. Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells. Exp Mol Med, 2019, 51(11): 1-20. |
| [20] | Amann T, Bataille F, Spruss T, Dettmer K, Wild P, Liedtke C, Mühlbauer M, Kiefer P, Oefner PJ, Trautwein C, Bosserhoff AK, Hellerbrand C. Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol, 2010, 176(3): 1433-1442. |
| [21] | Yang H, Jiang Z, Wang S, Zhao YB, Song XM, Xiao YF, Yang SM. Long non-coding small nucleolar RNA host genes in digestive cancers. Cancer Med, 2019, 8(18): 7693-7704. |
| [22] | Zhu QY, Yang HJ, Cheng P, Han Q. Bioinformatic analysis of the prognostic value of the lncRNAs encoding snoRNAs in hepatocellular carcinoma. Biofactors, 2019, 45(2): 244-252. |
| [23] | Adamczyk-Gruszka O, Horecka-Lewitowicz A, Gruszka J, Wawszczak-Kasza M, Strzelecka A, Lewitowicz P. FGFR-2 and epithelial-mesenchymal transition in endometrial cancer. J Clin Med, 2022, 11(18): 5416. |
| [24] | Maehara O, Suda G, Natsuizaka M, Shigesawa T, Kanbe G, Kimura M, Sugiyama M, Mizokami M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohashi S, Kagawa S, Kinugasa H, Naganuma S, Okubo N, Ohnishi S, Takeda H, Sakamoto N. FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma. Cancer Biol Ther, 2021, 22(5-6): 372-380. |
| [25] | Czaplinska D, Turczyk L, Grudowska A, Mieszkowska M, Lipinska AD, Skladanowski AC, Zaczek AJ, Romanska HM, Sadej R. Phosphorylation of RSK2 at Tyr 529 by FGFR2-p38 enhances human mammary epithelial cells migration. Biochim Biophys Acta, 2014, 1843(11): 2461-2470. |
| [26] | Cai SY, Yang YM, Jia BH, Wu ZH, Zhang JG, Shen JX, Qiu GX. Transcriptome-wide sequencing reveals molecules and pathways involved in neurofibromatosis type I combined with spinal deformities. Spine (Phila Pa 1976), 2020, 45(9): E489-E498. |
| [27] | Chaffee BR, Hoang TV, Leonard MR, Bruney DG, Wagner BD, Dowd JR, Leone G, Ostrowski MC, Robinson ML. FGFR and PTEN signaling interact during lens development to regulate cell survival. Dev Biol, 2016, 410(2): 150-163. |
| [28] | Nagaraju GP., Dariya B, Kasa P, Peela S, El-Rayes BF. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol, 2022, 86(Pt 3): 622-632. |
| [29] | Yang Y, Ren PW, Liu XF, Sun XY, Zhang CF, Du XJ, Xing BC. PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition. J Exp Clin Cancer Res, 2022, 41(1): 101. |
| [30] | Zhao JX, Wang F, Xu ZR, Fan YM. The epigenetic effect on pre-mRNA alternative splicing. Hereditas (Beijing), 2014, 36(3): 248-255. |
| [30] | 赵金璇, 王芳, 徐峥嵘, 范怡梅. 表观遗传调控pre-mRNA的选择性剪接. 遗传, 2014, 36(3): 248-255. |
| [31] | Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu QS, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, Hammerman PS. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res, 2013, 73(16): 5195-5205. |
| [32] | Taniguchi K, Sakai M, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakayama T, Ueda H, Nakagawa Y, Ito Y, Futamura M, Uno B, Otsuki Y, Yoshida K, Uchiyama K, Akao Y. PTBP1-associated microRNA-1 and -133b suppress the Warburg effect in colorectal tumors. Oncotarget, 2016, 7(14): 18940-18952. |
| [33] | Xie RH, Chen X, Chen ZY, Huang M, Dong W, Gu P, Zhang JT, Zhou QH, Dong W, Han JL, Wang XS, Li H, Huang J, Lin TX. Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM. Cancer Lett, 2019, 449: 31-44. |
| [34] | Kuranaga Y, Sugito N, Shinohara H, Tsujino T, Taniguchi K, Komura K, Ito Y, Soga T, Akao Y. SRSF3, a splicer of the PKM gene, regulates cell growth and maintenance of cancer-specific energy metabolism in colon cancer cells. Int J Mol Sci, 2018, 19(10): 3012. |
| [35] | Miao H, Wu F, Li Y, Qin CY, Zhao YY, Xie MF, Dai HY, Yao H, Cai HY, Wang QH, Song X, Li L. MALAT1 modulates alternative splicing by cooperating with the splicing factors PTBP1 and PSF. Sci Adv, 2022, 8(51): eabq7289. |
| [36] | Teles SP, Oliveira P, Ferreira M, Carvalho J, Ferreira P, Oliveira C. Integrated analysis of structural variation and RNA expression of FGFR2 and its splicing modulator ESRP1 highlight the ESRP1(amp)-FGFR2(norm)-FGFR2- IIIc(high) axis in diffuse gastric cancer. Cancers (Basel), 2019, 12(1): 70. |
| [37] | Warzecha CC, Shen SH, Xing Y, Carstens RP. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol, 2009, 6(5): 546-562. |
| [38] | Jones RB, Carstens RP, Luo Y, McKeehan WL. 5′- and 3′-terminal nucleotides in the FGFR2 ISAR splicing element core have overlapping roles in exon IIIb activation and exon IIIc repression. Nucleic Acids Res, 2001, 29(17): 3557-3565. |
| [39] | Simarro M, Mauger D, Rhee K, Pujana MA, Kedersha NL, Yamasaki S, Cusick ME, Vidal M, Garcia-Blanco MA, Anderson P. Fas-activated serine/threonine phosphoprotein (FAST) is a regulator of alternative splicing. Proc Natl Acad Sci USA, 2007, 104(27): 11370-11375. |
| [40] | Hovhannisyan RH, Warzecha CC, Carstens RP. Characterization of sequences and mechanisms through which ISE/ISS-3 regulates FGFR2 splicing. Nucleic Acids Res, 2006, 34(1): 373-385. |
| [41] | Yoshino M, Ishiwata T, Watanabe M, Matsunobu T, Komine O, Ono Y, Yamamoto T, Fujii T, Matsumoto K, Tokunaga A, Naito Z. Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol, 2007, 31(4): 721-728. |
| [42] | Ishiwata T, Friess H, Büchler MW, Lopez ME, Korc M. Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. Am J Pathol, 1998, 153(1): 213-222. |
| [43] | Kurban G, Ishiwata T, Kudo M, Yokoyama M, Sugisaki Y, Naito Z. Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. Oncol Rep, 2004, 11(5): 987-991. |
| [44] | Yamayoshi T, Nagayasu T, Matsumoto K, Abo T, Hishikawa Y, Koji T. Expression of keratinocyte growth factor/fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis. J Pathol, 2004, 204(1): 110-118. |
| [45] | Cho K, Ishiwata T, Uchida E, Nakazawa N, Korc M, Naito Z, Tajiri T. Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am J Pathol, 2007, 170(6): 1964-1974. |
| [46] | Zhang Y, Wang H, Toratani S, Sato JD, Kan M, McKeehan WL, Okamoto T. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci USA, 2001, 98(20): 11336-11340. |
| [47] | Matsubara A, Kan M, Feng S, McKeehan WL.Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res, 1998, 58(7): 1509-1514. |
| [48] | Ricol D, Cappellen D, El Marjou A, Gil-Diez-de-Medina S, Girault JM, Yoshida T, Ferry G, Tucker G, Poupon MF, Chopin D, Thiery JP, Radvanyi F. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene, 1999, 18(51): 7234-7243. |
| [49] | Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol, 2006, 7(2): 131-142. |
| [50] | Warzecha CC, Carstens RP. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol, 2012, 22(5-6): 417-427. |
| [51] | Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol, 2018, 13: 395-412. |
| [52] | Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene, 1997, 15(25): 3059-3065. |
| [53] | Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, Weinstein JN, Kenna Shaw for TCGA research network, Strausberg RL, Yao J. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res, 2013, 19(9): 2460-2472. |
| [54] | Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 2008, 14(19): 6146-6153. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
